Sherman Reeves, MD
Ophthalmology · Minneapolis, MNNPI 1205882560
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $215 of the $243 with a category attached, or 88.6%. Rxsight Inc accounts for 68.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $151 and has fallen 59.1% since, to $62 in 2025. That places this record below the midpoint for ophthalmology clinicians in MN, where the typical reported total is $290.
Across 8 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$165
- Glaukos Corporation$27
- Sun Pharmaceutical Industries Inc.$20
- Rayner Intraocular Lenses Limited$18
- Johnson & Johnson Surgical Vision, Inc.$13
Across 7 payments — averaging $15,640 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avedro Inc.$83K
- Glaukos Corporation$26K
What the payments were for
- Speaking & faculty fees$2811%
- Food & beverage$21589%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 3 | $165 |
| Glaukos Corporation | 2 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
How this compares
$243 in reported general payments places this provider in the 45th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 60 | $76,068 |
| XiidraLifitegrast | 42 | $67,796 |
| Prednisolone Acetate | 773 | $30,228 |
| Ketorolac Tromethamine | 474 | $7,321 |
| Gatifloxacin | 152 | $6,396 |
| ValacyclovirValacyclovir Hcl | 85 | $5,113 |
| Ofloxacin | 287 | $3,429 |
| Fluorometholone | 25 | $2,019 |
| Doxycycline Hyclate | 14 | $1,957 |
| MoxifloxacinMoxifloxacin Hcl | 103 | $1,582 |
| Latanoprost | 69 | $978 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $714 |
| ErythromycinErythromycin Base | 53 | $606 |
| Brimonidine Tartrate | 29 | $550 |
| Acyclovir | 13 | $440 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Minneapolis
- Edwin RyanMinneapolis$9.6M
- David HardtenMinneapolis$119K
- Sandra MontezumaMinneapolis$48K
- Sundeep DevMinneapolis$13K
- Silvia Orengo-NaniaMinneapolis$12K
- Robert MittraMinneapolis$6K
- David ParkeMinneapolis$6K
- Michael LeeMinneapolis$3K
- Huda SheheitliMinneapolis$3K
- Dinesh GoyalMinneapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.